Noticias y Actividades de Immunocore
Ejecutivos
Ver el organigrama con sus 29 ejecutivos principales
Biografías más buscadas en Immunocore
- Bahija Jallal, Chief Executive Officer and Director
- Siddharth Kaul, Non-Executive Director
- Peter Ratcliffe, Non-Executive Director
Recientes movimientos de ejecutivos en Immunocore
- Mohammed Dar que ha sido Head of Clinical Development and Chief Medical Officer, ha ascendido a Executive Vice President, Clinical Development and Chief Medical Officer (noticia publicada el 30 de enero de 2026).
- David Berman, Head of Research & Development, abandonará la empresa el 27 de feb.. de 2026 (noticia publicada el 30 de enero de 2026).
- Tina St. Leger, Chief Human Resources Officer, ha dejado la empresa (noticia publicada el 1 de diciembre de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Immunocore.
Biotecnología
Immunocore tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).
Popular M&A news in Biotecnología
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado el 17 de julio de 2026).
- GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publicado el 15 de julio de 2026).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Immunocore
- Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
- Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
- Immunocore to present at upcoming investor conferences :: Immunocore PLC
- Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
- Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
- Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
- Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
- Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
- View more press releases Close
Redes sociales sobre Immunocore
- Immunocore en Wikipedia, Google News y Yahoo Finance
- Immunocore en LinkedIn, Twitter y YouTube
